Movement disorders:帕金森氏征,多巴胺代谢和大脑血流代谢有何关系?

2022-06-23 Freeman MedSci原创

在PD和四次重复的tauopathy中,前额叶灌注与同侧黑质多巴胺能功能有关

帕金森病(PD)是一种神经退行性疾病,其特征是黑质多巴胺能神经元逐渐丧失,受影响细胞的胞质中存在路易体。临床特征是运动迟缓、僵硬和静止性震颤,此外还有非运动症状,如自主神经、认知、精神、感觉和睡眠障碍,这些症状可能先于运动功能障碍。多巴胺替代疗法可缓解PD的运动功能障碍,这意味着突触后的多巴胺能系统被相对保留。这种有效性将PD与非典型帕金森综合征(APS)区分开来,包括多系统萎缩(MSA)、进行性核上麻痹(PSP)和皮质基质综合征(CBS)。

 

图1: 论文封面图

由于APS的运动功能障碍通常对多巴胺能治疗无效,与PD相比,APS的疾病进展和预后不佳。因此,早期和准确的诊断是至关重要的。多巴胺转运体(DAT)单光子发射计算机断层扫描(SPECT)使用放射性配体,如123I-N-ω-氟丙基-2β-甲氧羰基-3β-{4-碘苯基}诺托品(123I-FP-CIT),可以使纹状体突触前多巴胺能功能可视化。纹状体DAT结合异常减少是PD的强制性发现,并可能有助于早期诊断,以区别于原发性震颤患者。

尽管如此,APS的特点是纹状体DAT结合率低,使用低纹状体DAT结合率很难区分PD和APS。另一个限制是随着正常老化,黑质体功能减退,使得在不同年龄段的人中量化纹状体DAT结合具有挑战性。最近,为了克服这个问题,在一项大规模的多中心定量研究中,引入了一种方法来规范123I-FP-CIT SPECT中与年龄有关的下降和与扫描仪有关的差异。


脑血流(CBF)和脑葡萄糖代谢图像对帕金森病的鉴别诊断是有效的。值得注意的是,帕金森病患者在额顶联合区的代谢或灌注减少:这被称为帕金森病相关共变模式(PDRP)。

PDRP分数的大小可以通过多巴胺能治疗来调节,尽管多巴胺替代的影响在不同的脑区可能有所不同。


监督机器学习是一种人工智能,最近被应用于从健康参与者中鉴别诊断PD的神经影像学,并可能作为一种新的诊断方法。尽管每种成像模式都可以有效地区分帕金森病,但不同类型的成像模式之间的关系却不太清楚。因此,有监督的机器学习方法可用于评估多模态影像在区分帕金森病的功效。


藉此,日本千叶大学的Yoshikazu Nakano等人,研究帕金森病患者的CBF和DAT SPECT之间的关系,确定每种帕金森病患者的纹状体多巴胺能与CBF的相关性,并比较不同的疾病。

58名PD患者和71名APS患者(24名多系统萎缩,21名进行性核上麻痹,26名皮质基底综合征)接受了123 I-IMP和123 I-FP-CIT单光子发射计算机断层扫描。对每一组进行了CBF和纹状体DAT结合的多元回归分析。通过机器学习和接收器操作特征曲线预测PD概率。

 

图2:论文结果图

他们发现:PD组显示更多的纹状体DAT结合与同侧前额叶灌注呈正相关,与双侧小脑灌注呈负相关。

在皮质基质综合征中,纹状体DAT结合与同侧前额叶灌注呈正相关,与对侧腹前灌注呈负相关。

在Richardson综合征中,纹状体DAT结合与同侧腹前皮层和基底神经节的灌注呈正相关。机器学习显示,CBF和DAT的组合比单独的CBF(0.67)或DAT(0.50)更能区分PD与APS(曲线下面积[AUC]=0.87)。


该研究的重要意义在于发现了:在PD和四次重复的tauopathy中,前额叶灌注与同侧黑质多巴胺能功能有关。这种双tracer的额叶与纹状体的关系可有效地作为划分PD与APS的一种诊断工具。

 

原文出处:
Nakano Y, Hirano S, Kojima K, et al. Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders. _Movement Disorders_. Published online March 14, 2022:mds.28981. doi:[10.1002/mds.28981](https://doi.org/10.1002/mds.28981)

 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784518, encodeId=a13e1e8451836, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 14 00:54:46 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013904, encodeId=23b320139049d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 12 07:54:46 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077702, encodeId=c94820e77028b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Oct 25 09:54:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042285, encodeId=b7552042285fb, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Mar 14 07:54:46 CST 2023, time=2023-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878544, encodeId=4d1b18e8544ad, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu May 18 09:54:46 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738134, encodeId=e2c31e3813469, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Thu Aug 04 00:54:46 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784518, encodeId=a13e1e8451836, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 14 00:54:46 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013904, encodeId=23b320139049d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 12 07:54:46 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077702, encodeId=c94820e77028b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Oct 25 09:54:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042285, encodeId=b7552042285fb, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Mar 14 07:54:46 CST 2023, time=2023-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878544, encodeId=4d1b18e8544ad, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu May 18 09:54:46 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738134, encodeId=e2c31e3813469, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Thu Aug 04 00:54:46 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784518, encodeId=a13e1e8451836, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 14 00:54:46 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013904, encodeId=23b320139049d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 12 07:54:46 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077702, encodeId=c94820e77028b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Oct 25 09:54:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042285, encodeId=b7552042285fb, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Mar 14 07:54:46 CST 2023, time=2023-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878544, encodeId=4d1b18e8544ad, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu May 18 09:54:46 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738134, encodeId=e2c31e3813469, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Thu Aug 04 00:54:46 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784518, encodeId=a13e1e8451836, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 14 00:54:46 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013904, encodeId=23b320139049d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 12 07:54:46 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077702, encodeId=c94820e77028b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Oct 25 09:54:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042285, encodeId=b7552042285fb, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Mar 14 07:54:46 CST 2023, time=2023-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878544, encodeId=4d1b18e8544ad, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu May 18 09:54:46 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738134, encodeId=e2c31e3813469, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Thu Aug 04 00:54:46 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784518, encodeId=a13e1e8451836, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 14 00:54:46 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013904, encodeId=23b320139049d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 12 07:54:46 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077702, encodeId=c94820e77028b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Oct 25 09:54:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042285, encodeId=b7552042285fb, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Mar 14 07:54:46 CST 2023, time=2023-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878544, encodeId=4d1b18e8544ad, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu May 18 09:54:46 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738134, encodeId=e2c31e3813469, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Thu Aug 04 00:54:46 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
    2023-05-18 anminleiryan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1784518, encodeId=a13e1e8451836, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 14 00:54:46 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013904, encodeId=23b320139049d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 12 07:54:46 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077702, encodeId=c94820e77028b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Oct 25 09:54:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042285, encodeId=b7552042285fb, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Mar 14 07:54:46 CST 2023, time=2023-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878544, encodeId=4d1b18e8544ad, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu May 18 09:54:46 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738134, encodeId=e2c31e3813469, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Thu Aug 04 00:54:46 CST 2022, time=2022-08-04, status=1, ipAttribution=)]

相关威廉亚洲官网

Movement disorder:-帕金森患者,大脑代谢和步态有何关系?

两个新的与步态有关的大脑网络,在静止状态下葡萄糖代谢发生了改变

Movement disorders:去甲肾上腺素能活动,对焦虑诱发的冻结步态,有何影响?

与焦虑有关的交感神经唤醒可以促进分布式皮质网络之间的 "交叉对话 "增加,最终表现为阵发性的步态冻结发作。

MOVEMENT DISORDERS:2型糖尿病与帕金森病更快进展有关

T2DM与帕金森病更快的疾病进展有关,它可能是缓解帕金森症状和减缓残疾和痴呆进展的目标。

Movement disorders:帕金森患者,糖尿病可加剧神经损伤

流行病学研究令人信服地表明糖尿病和帕金森病(PD)之间存在联系。记录联系的队列研究、荟萃分析和孟德尔随机化分析发现,有证据表明糖尿病患者的PD风险增加。

Science Translational Medicine:帕金森病治疗的一大步:LRRK2抑制剂临床试验评估

全世界有超过1000万人患有帕金森病,每年还有约60000名新患者确诊。患者大脑中产生多巴胺的神经元丧失,影响运动和认知,导致出现震颤、肌肉僵硬、意识模糊和痴呆等症状。

拓展阅读

MIND饮食:能预防老年痴呆和帕金森病?

健脑饮食,又称 MIND 饮食,是一种针对大脑健康的饮食法,这种饮食相对较新颖,不属于生酮饮食,但是低碳水饮食的一种。它结合了地中海饮食和 DASH 饮食。

Neurology:帕金森病患者结构脑网络弹性和拓扑结构的病理改变

本研究结果强调,区域网络干扰的解释比以前认为的要复杂得多。

BMJ子刊 | 瑞金医院陈生弟教授团队:长期太极拳训练对帕金森病的影响:一项为期 3.5 年的随访队列研究

太极拳训练对帕金森病有长期的有益影响,可以改善运动和非运动症状,减少并发症。

Nat Commun:结合机器学习与血浆蛋白质组质谱分析可提前7年预测帕金森病,准确率达79%

该研究表明,血浆蛋白质组检测或有助于在运动症状出现前7年预测PD的发生。

European Radiology:帕金森病患者脑铁氧代谢的时空变化特征

氧摄取分数(OEF) 是脑氧代谢相关的生理指标,反映脑动脉供血的氧摄取百分比。其中,PD患者脑组织OEF值可作为评估脑氧代谢异常的无创性临床指标。

Brain:多巴胺和深部脑刺激加速帕金森病患者的意愿性动作神经动力学

多巴胺和深部脑刺激通过加速和改变帕金森病患者自愿动作的神经动力学来缓解运动不能,具体表现为将皮质-丘脑底核耦合的振荡信息流从抗运动的β节律转移到促运动的θ节律。

2024 NICE 诊断威廉亚洲博彩公司 :帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定威廉亚洲博彩公司 :左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10